Cancer

Frequency Exchange Welcomes Former NHL Star and Current President of the Boston Bruins Cam Neely to Its Advisory Board

VANCOUVER, BC / ACCESSWIRE / November 22, 2024 / Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ)(OTC PINK:FRECF) is…

2 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated…

2 months ago

Result of General Meeting

November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the…

2 months ago

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…

2 months ago

EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One® to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America Meeting

         Early feasibility work demonstrates Focal One system’s ability to generate histotripsy lesions ex vivo LYON, France, November 22, 2024…

2 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced…

2 months ago

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research…

2 months ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to…

2 months ago

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024…

2 months ago